Drug Profile


Alternative Names: YH-IMD2; YH_IMD2

Latest Information Update: 10 Dec 2015

Price : $50

At a glance

  • Originator Yuhan
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Hyperlipidaemia; Hypertension

Most Recent Events

  • 10 Dec 2015 Discontinued - Preclinical for Hypertension in South Korea (PO)
  • 10 Dec 2015 Discontinued - Preclinical for Hyperlipidaemia in South Korea (PO)
  • 23 Aug 2012 Preclinical trials in Hyperlipidaemia in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top